FPI-2068 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 97% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FPI-2068’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FPI-2068 overview
FPI-2068 is under development for the treatment of metastatic solid tumor, colorectal cancer, recurrent head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and non-small cell lung cancer. It which contains an bispecific antibody fused with actinium 225 radioisotope through fast clear linker. It acts by targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met). It is administered through intravenous route.
Fusion Pharmaceuticals overview
Fusion Pharmaceuticals, a subsidiary of AstraZeneca Plc, is a clinical-stage biopharmaceutical company that develops targeted alpha-particle radio therapeutics for the treatment of cancers. It offers pipeline products such as FPI-1434, FPI-2059, FPI-2265 and FPI-1434. The company’s pipeline products treat multiple cancers like head and neck bladder cancer, colorectal cancer and gastric cancers. Fusion Pharmaceuticals carters its products under brand Keytruda. It operates in the US and Canada. Fusion Pharmaceuticals is headquartered in Hamilton, Ontario, Canada.
For a complete picture of FPI-2068’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
